In addition to the anti-CD20 type I mAbs Rituximab and Ofatumumab and the glycoengineered type II mAb Obinutuzumab, now there is also the novel Fc-engineered Ocaratuzumab http://en.m.wikipedia.org/wiki/Ocaratuzumab.
It says that in addition to targeting B-cell cancers it's also being investigated to treat autoimmune conditions such as RA:
Low Doses Of Ocaratuzumab, A Fc- And Fab-Engineered Anti-CD20 Antibody, Result In Rapid And Sustained Depletion Of Circulating B-Cells In Rheumatoid Arthritis Patients.
It says that in addition to targeting B-cell cancers it's also being investigated to treat autoimmune conditions such as RA:
Low Doses Of Ocaratuzumab, A Fc- And Fab-Engineered Anti-CD20 Antibody, Result In Rapid And Sustained Depletion Of Circulating B-Cells In Rheumatoid Arthritis Patients.
Even when administered at doses that are less than 100 fold that of rituximab, ocaratuzumab demonstrates rapid and prolonged B-cell depletion in RA patients. The majority of the patients treated with very low doses of ocaratuzumab demonstrated protracted B-cell depletion lasting for three months, with one patient recovering B-cells more than one year after receiving 7.5 mg of drug. Ocaratuzumab may provide a therapeutic option for patients with autoimmune diseases, especially those with the low affinity FcgRIIIa phenotype, who have not received optimal benefit from conventional monoclonal antibodies. Furthermore, ocaratuzumab can potentially be given at doses much smaller than that of the conventional antibodies, possibly permitting subcutaneous administration.
Last edited: